The most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss ...

Warhammer 40,000: Wrath & Glory lets players build their groups from different archetypes. They are brought together as ...

Gilead Sciences (GILD ... As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into ...

With the launch of the Global Partner Program, Aisera is poised to drive a new era of digital transformation, enabling ...

A new study published has revealed that Gilead Sciences’ Lenacapavir has ... attacks and weakens a person’s immune system by targeting white blood cells. Acquired immunodeficiency syndrome ...

Fan Zhang, PhD, of the University of Colorado Department of Medicine sees artificial intelligence as a pathway to combating an intractable enemy: rheumatoid arthritis.

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor ...

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences ... brakes" of the immune system.

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Gilead Sciences' cell therapy Kite Pharma has ... T cells are part of the adaptive immune system, so need to be activated before they attack cancer cells that present antigens.